Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life
|
Jan 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.
|
Jul 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution
|
Sep 2014
|
Blood
|
aplastic anemia
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
Allogeneic Stem Cell Transplantations for elderly patients with Myelodysplastic Syndrome
|
Apr 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
|
Apr 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
|
May 2017
|
Blood
|
acute myeloid leukemia (AML)
|
Genetics of Progression From MDS to Secondary Leukemia
|
Jul 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
|
Aug 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|